Pomerantz Law Firm Takes Action on Behalf of NeoGenomics Investors

Pomerantz Investigates NeoGenomics: A Call to Investors

On August 16, 2025, Pomerantz LLP announced that it is launching an investigation into NeoGenomics, Inc. (NASDAQ: NEO) regarding possible claims of securities fraud and other unlawful business practices impacting investors. The firm urges affected investors to reach out for potential involvement in a class-action lawsuit.

Investors are reeling from disappointing financial results disclosed by NeoGenomics in a press release dated July 29, 2025. The company reported a revenue of $181.3 million, which fell short of market expectations. Additionally, the company faced a staggering net loss of $45.1 million for the quarter. This disappointing performance caused the company to revise its 2025 revenue forecast downward, adjusting it to a range of $720 million to $726 million, a significant drop from a previous projection of approximately $753 million.

Such financial missteps have raised concerns among investors, particularly in light of the substantial adjustment to NeoGenomics' adjusted EBITDA projections, which now sit between $41 million and $44 million compared to earlier estimates of $55 million to $58 million. Following the announcement of these results, NeoGenomics' stock price dropped by $1.21 per share—or 18.73%—closing at $5.25 on the same day.

The investigation by Pomerantz LLP focuses on whether NeoGenomics, along with its various officers or directors, has engaged in any illicit activities that might be considered securities fraud. Investors who feel their interests have been jeopardized by these developments are encouraged to contact Pomerantz for guidance and further information on how to proceed legally.

Pomerantz LLP has established a reputation as a leader in corporate, securities, and antitrust class-action litigation, with a history dating back over 85 years. Founded by Abraham L. Pomerantz, known as the dean of the class-action bar, the firm has a long-standing tradition of fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and other forms of corporate misconduct. Over the years, Pomerantz has successfully secured multimillion-dollar settlements on behalf of class members, indicating their expertise in navigating complex legal landscapes.

For investors seeking more details or wishing to participate in this investigation, they can contact Danielle Peyton at the Pomerantz Law Firm through her email at [email protected] or via telephone at 646-581-9980, extension 7980.

As circumstances evolve, it is crucial for investors to stay informed and vigilant regarding their financial interests. The ongoing investigation by Pomerantz likely signifies a pivotal moment for stakeholders within NeoGenomics as they weigh their options and assess the legal ramifications of the company’s financial performance.

In conclusion, it’s essential for those impacted by NeoGenomics' recent financial disclosures to take action swiftly. The potential for recovery through legal means may hinge on timely participation in the investigation spearheaded by Pomerantz LLP. Investors are therefore encouraged to act quickly to ensure their voices are heard in this unfolding situation.